24TOPNEWSFinancial IntelligenceBETA中文
← Overview
Healthcare · 13.3

Biotechnology

Quantified news impact based on deduplicated, quality-reviewed events in a single 60-day window.

Average net impact+22weighted per event
Average gross impact27absolute weighted average
Events28same period
Confidence76%model average
Raw intensity58before weighting
Previous period0net impact
Gross changeInsufficient base
Diffusion speed0.5 / day
Concentration5%
Direction disagreement20%
Source independence100%12 sources
IMPACT TREND

60-day effective impact

Positive 24 · Negative 2 · Mixed 2

Current periodPrevious period
TIME HORIZON

Impact duration

Immediate0%0 cumulative effective impact
Short term37%278 cumulative effective impact
Medium term51%381 cumulative effective impact
Long term13%95 cumulative effective impact
CO-IMPACT

Related industries

13.1Pharmaceuticals13 shared events+3010.4Artificial Intelligence6 shared events+2213.15Pharmaceutical R&D Services5 shared events+1810.1Semiconductor Value Chain4 shared events+2213.5Medical Equipment3 shared events+2113.2Traditional Chinese Medicine3 shared events+178.3New Energy Vehicles3 shared events+1310.5Robotics3 shared events+13
EVENT EVIDENCE

Events ranked by effective impact

Page 3 of 3 · 28 events

Macro2
01
Macropositive

Beijing BDA H1 2026 GDP Reaches 1967.8 Hundred Million Yuan, Up 6.1%

Beijing Economic-Technological Development Area (BDA) reported H1 2026 GDP of 1967.8 hundred million yuan, up 6.1% year-on-year. Industrial output neared 3600 hundred million yuan, with leading industries accounting for over 90% of total. New-generation information technology output surged 37.5%, while robotics and smart manufacturing grew 12.3%. Foreign trade reached 1188.5 hundred million yuan, up 33.8%. Corporate R&D spending rose nearly 30%, and the area added 13 new first-set products, ranking first in Beijing.

Effective
+13
Intensity
40
Confidence
65%
Horizon
Short term
02
Macropositive

Shenwan Hongyuan Has Invested in Wu Wenxinqiong, Xijing Technology; Supported Anji Technology's Convertible

On July 28, 2026, Shenwan Hongyuan Securities Chairman Liu Jian spoke at the Science and Technology Innovation Industry Integration and Development Conference in Shanghai. He highlighted the firm's investments in Wu Wenxinqiong and Xijing Technology, and its support for Anji Technology's convertible bond refinancing on the STAR Market and Zhida Technology's Hong Kong IPO. The firm also deepened its research, investment, and investment banking integration, establishing industry research and launching service stations in 2025.

Effective
+8
Intensity
30
Confidence
50%
Horizon
Medium term
Industries2
01
Industriespositive

China Issues TCM Revitalization Plan; Drug Registration Approvals and Medical Services Index Surge 4%

A-share medical services index rose over 4% on July 27 as multiple drug firms, including ST Wanbang, received registration certificates. Wanbang Pharmaceutical surged over 13%, while several other stocks gained over 6%. The National Administration of Traditional Chinese Medicine and the National Development and Reform Commission issued the 15th Five-Year Plan for TCM revitalization, covering the 2026-2030 period.

Effective
+16
Intensity
40
Confidence
75%
Horizon
Medium term
02
Industriesmixed

China's 12th Batch Drug Central Procurement Covers 65 Varieties, Introduces 'Volume-Less' Win and Reference

China's 12th batch of national centralized drug procurement has been launched, covering 65 varieties across therapeutic areas including hypertension, diabetes, oncology, organ transplant anti-rejection, and anti-infectives. The new rules introduce a 'volume-less' winning mechanism that uses statistical standard deviation to prevent extreme low pricing, and a separate channel for reference preparations that allows winning without volume commitment. Reporting by drug brand is now fully implemented, with 45,000 medical institutions and over 500 companies participating. The most competitive variety has more than 50 bidders.

Effective
0
Intensity
50
Confidence
75%
Horizon
Short term
Companies4
01
Companiespositive

Angel Yeast Subsidiary to Invest RMB 370 Million in Synthetic Biology Pilot Base

Angel Yeast Co. , Ltd. (600298) announced on July 27 that its wholly-owned subsidiary, the Enzyme Preparation Company, plans to invest RMB 370 million to build a new synthetic biology pilot-scale validation base. The project has a construction period of 16 months.

Effective
+19
Intensity
50
Confidence
75%
Horizon
Medium term
02
Companiespositive

FedEx Launches Life Sciences Unit Focused on GLP-1 and Temperature-Controlled Medical Logistics

FedEx launched FedEx Life Sciences in 2026, focusing on healthcare logistics. The unit generates about $10 billion in annual revenue, over 10% of total. Chief Customer Officer Brie Carere said the medical logistics market opportunity is about $80 billion, with 7% CAGR, including 20% growth for GLP-1 drugs and 25% for cell and gene therapies. FedEx uses five temperature zones and real-time tracking; 40% of medical clients use FedEx Surround. Competitor UPS invested $48 million in its network, reporting $11.2 billion in medical revenue. FedEx CEO Raj Subramanian said nearly half of revenue growth is from B2B. FedEx targets $98 billion revenue by 2029.

Effective
+17
Intensity
40
Confidence
70%
Horizon
Medium term
03
Companiespositive

Apeloa's Ante Yutai, WuXi Biologics, Duoning Sign Five-Year Strategic Framework without Specific Projects

Apeloa Pharmaceutical's controlled subsidiary Zhejiang Ante Yutai Biotechnology has signed a five-year strategic cooperation framework agreement with WuXi Biologics and Shanghai Duoning Biotechnology. The partnership aims to advance biopharmaceutical pipeline development, build industrialization capacity, and improve the supply chain. The agreement does not specify projects or amounts and will not materially affect the company's current fiscal year results.

Effective
+2
Intensity
15
Confidence
55%
Horizon
Long term
04
Companiesmixed

Bio-Thera Solutions Expects First-Half 2026 Loss of 230-290 Million RMB on Higher R&D Costs

Bio-Thera Solutions expects a net loss of 230 million to 290 million RMB for the first half of 2026, widening from the prior period as research and development expenses rose by more than 100 million RMB. Sales of its adalimumab injection (Geloli) and tocilizumab injection (Shiruli) increased steadily year-on-year, but expense growth outpaced revenue growth, leading to the larger loss.

Effective
0
Intensity
30
Confidence
80%
Horizon
Short term